Scarica l'app Stockscreener
113.33
2.33%
2.58
Precedente Chiudi:
$110.75
Aprire:
$111.26
Volume 24 ore:
772.32K
Relative Volume:
0.93
Capitalizzazione di mercato:
$6.87B
Reddito:
$3.99B
Utile/perdita netta:
$463.16M
Rapporto P/E:
15.96
EPS:
7.1
Flusso di cassa netto:
$1.10B
1 W Prestazione:
+0.11%
1M Prestazione:
+2.78%
6M Prestazione:
-16.32%
1 anno Prestazione:
+4.77%
Intervallo 1D:
$110.26
$113.42
Intervallo di 1 settimana:
$105.00
$113.54
Portata 52W:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
113.33 | 6.72B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN
Using flow based indicators on Jazz Pharmaceuticals plcTechnical Analysis of Growth Stock Opportunities - Newser
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock - Yahoo Finance
FDA Grants Accelerated Approval to Dordaviprone For Diffuse Midline Glioma - Pharmacy Times
How to integrate Jazz Pharmaceuticals plc into portfolio analysis tools - Newser
Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted - insights.citeline.com
Jazz Pharmaceuticals stock surges 4.8% on FDA approval for Modeyso treatment - AInvest
Jazz Pharma wins FDA nod for brain tumor drug (JAZZ:NASDAQ) - Seeking Alpha
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript - Insider Monkey
FDA approval of Modeyso for glioma - The Pharma Letter
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - MSN
Beyond the Balance Sheet: What SWOT Reveals About Jazz Pharmaceu - GuruFocus
Jazz Earnings: Xywav and Epidiolex Drive Growth; US Approval for Chimerix's Dordaviprone Promising - Morningstar
Chimerix buyout a win for Jazz with FDA nod for rare glioma drug - BioWorld MedTech
US FDA approves Jazz Pharma's drug for rare brain tumor - Reuters
Rising Star: Quinn Emanuel's Frank Calvosa - Law360
FDA Breakthrough: Jazz Pharma's New Drug Targets Deadly Brain Tumor with No Previous Treatment - Stock Titan
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma - Ariva
Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView
What data driven models say about Jazz Pharmaceuticals plc’s futureFree Triple Digit Return Stock Predictions - Newser
Jazz Pharmaceuticals plc 2025 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... By GuruFocus - Investing.com Canada
Jazz: Q2 Earnings Snapshot - Greenwich Time
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... - Yahoo Finance
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should KnowTechnical Analysis of Growth Stock Opportunities - Newser
Using data tools to time your Jazz Pharmaceuticals plc exitFree Wealth Building Stock Market Ideas - Newser
Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition - TipRanks
Jazz Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Jazz Pharmaceuticals Sticks To Its Game Plan Despite Setbacks - Finimize
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Jazz Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Jazz Pharmaceuticals misses on Q2 earnings, shares fall By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals misses on Q2 earnings, shares fall - Investing.com
Jazz Pharma earnings missed by $0.63, revenue topped estimates - Investing.com South Africa
Jazz Pharmaceuticals Q2 revenue up 2% - MarketScreener
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q2 Adjusted Loss $8.25 per Share, vs. FactSet Est Loss of $7.61 - MarketScreener
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance - PR Newswire
Narcolepsy Market to Reach New Heights in Growth by 2034, - openPR.com
Narcolepsy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts| Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical - Barchart.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) investors are sitting on a loss of 25% if they invested three years ago - Yahoo Finance
How Jazz Pharmaceuticals plc stock reacts to Fed policy changesSwing Entry Insight With Forecast Accuracy - Newser
What MACD signals say about Jazz Pharmaceuticals plcOversold Opportunity Scanner with RSI Data - Newser
Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results - MSN
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):